Background/Aims The histological criteria in the 1999 and 2008 scoring systems proposed by the International Autoimmune Hepatitis Group (IAIHG) have their inherent limitations in diagnosing autoimmune hepatitis (AIH). In this study, we evaluated the histology components of four scoring systems (1. revised original scoring system [“1999 IAIHG”], 2. simplified scoring system [“2008 IAIHG”], 3. modified histologic criteria [“2017 UCSF”], and 4. a new histologic criteria proposed by the International AIH Pathology Group [“2022 IAHPG”]) in AIH patients.
Methods Medical records and liver biopsies were retrospectively reviewed for 68 patients from two independent medical institutions, diagnosed with AIH based on the 1999 IAIHG system between 2006 and 2016. The histological features were reviewed in detail, and the four histological scoring systems were compared.
Results Out of the 68 patients, 56 (82.4%) patients met the “probable” or “definite” AIH criteria of the 2008 IAIHG system, and the proportion of histologic score 2 (maximum) was 40/68 (58.8%). By applying the 2017 UCSF criteria, the number of histology score 2 increased to 60/68 (88.2%), and “probable” or “definite” AIH cases increased to 61/68 (89.7%). Finally, applying the 2022 IAHPG histology score resulted in the highest number of cases with histologic score 2 (64/68; 94.1%) and with a diagnosis of “probable” or “definite” AIH (62/68; 91.2%).
Conclusions The recently proposed UCSF/IAHPG histological criteria increased the histology score of AIH. Substituting the histology component of the 2008 IAIHG system with the 2022 IAHPG criteria increased the sensitivity for diagnosing AIH (≥“Probable AIH”) from 82.4% to 91.2%.
Citations
Citations to this article as recorded by
Quo vadis autoimmune hepatitis? - Summary of the 5th international autoimmune hepatitis group research workshop 2024 Bastian Engel, David N. Assis, Mamatha Bhat, Jan Clusmann, Joost PH. Drenth, Alessio Gerussi, María-Carlota Londoño, Ye Htun Oo, Ida Schregel, Marcial Sebode, Richard Taubert JHEP Reports.2025; 7(2): 101265. CrossRef
Histopathology of Autoimmune Hepatitis: An Update Despoina Myoteri, Stratigoula Sakellariou, Dina G. Tiniakos Advances in Anatomic Pathology.2025; 32(6): 414. CrossRef
EASL Clinical Practice Guidelines on the management of autoimmune hepatitis George Dalekos, Nikolaos Gatselis, Joost P. Drenth, Michael Heneghan, Marianne Jørgensen, Ansgar W. Lohse, Maria Londoño, Luigi Muratori, Maria Papp, Marianne Samyn, Dina Tiniakos, Ana Lleo Journal of Hepatology.2025; 83(2): 453. CrossRef
Evaluation of the histological scoring systems of autoimmune hepatitis: A significant step towards the optimization of clinical diagnosis Atsumasa Komori Clinical and Molecular Hepatology.2024; 30(2): 157. CrossRef
Reply to: “Evaluation of the histological scoring systems of autoimmune hepatitis: A significant step towards the optimization of clinical diagnosis” Haeryoung Kim, Sook-Hyang Jeong Clinical and Molecular Hepatology.2024; 30(2): 291. CrossRef
Reply to correspondence on “Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity” Atsumasa Komori Clinical and Molecular Hepatology.2024; 30(4): 1035. CrossRef
The utility of the mHAI scoring system in pediatric autoimmune hepatitis diagnosis and its association with treatment response Wei Chen, Gillian Noel, Mansi Amin, Fengming Chen Annals of Diagnostic Pathology.2024; 73: 152381. CrossRef
Diagnosis and Treatment of Patients with Autoimmune Hepatitis (Experts’ Agreement) Yu. G. Sandler, E. V. Vinnitskaya, K. L. Raikhelson, K. V. Ivashkin, S. N. Batskikh, E. N. Aleksandrova, D. T. Abdurakhmanov, D. I. Abdulganieva, I. G. Bakulin, A. O. Bueverov, S. L. Vorobyev, O. A. Gerasimova, A. I. Dolgushina, M. S. Zhuravleva, L. Yu. I Russian Journal of Gastroenterology, Hepatology, Coloproctology.2024; 34(6): 100. CrossRef
Tenofovir disoproxil fumarate (TDF) is effective against chronic hepatitis B (CHB) infection and its use is increasing rapidly worldwide. However, it has been established that TDF is associated with renal toxicity in human immunodeficiency virus-infected patients, while severe or symptomatic TDF-associated nephrotoxicity has rarely been reported in patients with CHB. Here we present two patients with TDF-associated nephrotoxicity who were being treated for CHB infection. The first patient was found to have clinical manifestations of proximal renal tubular dysfunction and histopathologic evidence of acute tubular necrosis at 5 months after starting TDF treatment. The second patient developed acute kidney injury at 17 days after commencing TDF, and he was found to have membranoproliferative glomerulonephritis with acute tubular injury. The renal function improved in both patients after discontinuing TDF. We discuss the risk factors for TDF-associated renal toxicity and present recommendations for monitoring renal function during TDF therapy.
Citations
Citations to this article as recorded by
Review Article: Renal Safety Profiles of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, and Entecavir for the Treatment of Chronic Hepatitis B Infection—General and Special Populations Lung‐Yi Mak, Tsung‐Hui Hu, Desmond Y. H. Yap Alimentary Pharmacology & Therapeutics.2026; 63(7): 945. CrossRef
Urinary Levels of Neutrophil Gelatinase-associated Lipocalin and Cystatin C in Patients with Hepatitis B on Tenofovir Treatment Shivani Rani, Himanshu Dandu, Ambuj Yadav, Mahak Lamba, Amit Goel, Wahid Ali, Virendra Atam, Sumit Rungta, Medhavi Gautam, Atin Singhai Journal of The Association of Physicians of India.2025; 73(2): 13. CrossRef
Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients David Sooik Kim, Soo Young Park, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Kwang-Hyub Han, Yu Rim Lee, Won Young Tak, Young Oh Kweon, Inkyung Jung, Minkyung Han, Eun Hwa Kim, Sang Hoon Ahn, Seung Up Kim Journal of Korean Medical Science.2021;[Epub] CrossRef
Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B Young Youn Cho, Young Chang, Joon Yeul Nam, Hyeki Cho, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim Gut and Liver.2020; 14(2): 225. CrossRef
Entecavir and tenofovir on renal function in patients with hepatitis B virus‐related hepatocellular carcinoma Mi Young Jeon, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Kwang‐Hyub Han, Sang Hoon Ahn, Seung Up Kim Journal of Viral Hepatitis.2020; 27(9): 932. CrossRef
Editorial: tenofovir disoproxil fumarate vs entecavir in patients with chronic hepatitis B and renal impairment—still an open issue Sung Won Lee, Seung Up Kim Alimentary Pharmacology & Therapeutics.2020; 52(5): 889. CrossRef
Tenofovir does not induce renal dysfunction compared to entecavir in post-liver-transplant hepatitis B virus patients Sang Jin Kim, Jinsoo Rhu, Seo Hee Lee, Jong Man Kim, Gyu-Seong Choi, Kyunga Kim, Jae-Won Joh Annals of Surgical Treatment and Research.2020; 99(3): 180. CrossRef
A severe case of tenofovir-associated acute kidney injury requiring hemodialysis in a patient with chronic hepatitis B A Young Cho, Ju Hwan Oh, Hee-Chan Moon, Gum Mo Jung, Young Suk Lee, Yeong Jin Choi, In O Sun, Kwang Young Lee Kidney Research and Clinical Practice.2020; 39(3): 373. CrossRef
Renal Dysfunction and Tubulopathy Induced by High-Dose Tenofovir Disoproxil Fumarate in C57BL/6 Mice Eungyeong Jang, Jong Kil Lee, Kyung-Soo Inn, Eun Kyoung Chung, Kyung-Tae Lee, Jang-Hoon Lee Healthcare.2020; 8(4): 417. CrossRef
Application of High-Performance Liquid Chromatography for Simultaneous Determination of Tenofovir and Creatinine in Human Urine and Plasma Samples Patrycja Olejarz, Grażyna Chwatko, Paweł Kubalczyk, Krystian Purgat, Rafał Głowacki, Kamila Borowczyk Pharmaceuticals.2020; 13(11): 367. CrossRef
Tenofovir-Associated Acute Kidney Disease: Is it Different in HIV- and HBV-Infected Patients? Fatemeh Ghasemi, Mohammadreza Salehi, Niloofar Khoshnam Rad, Hossein Khalili American Journal of Therapeutics.2019; 26(5): e639. CrossRef
Tenofovir and Entecavir Have Similar Renal Adverse Events on Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization Young Youn Cho, Young Hwan Choi, Su Jong Yu, Eun Ju Cho, Jeong-Hoon Lee, Yoon Jun Kim, Jung-Hwan Yoon Journal of Liver Cancer.2019; 19(2): 128. CrossRef
Effect of tenofovir on renal function in patients with chronic hepatitis B Woo Jin Jung, Jae Young Jang, Won Young Park, Soung Won Jeong, Hee Jeong Lee, Sang Joon Park, Sae Hwan Lee, Sang Gyune Kim, Sang-Woo Cha, Young Seok Kim, Young Deok Cho, Hong Soo Kim, Boo Sung Kim, Suyeon Park, Baigal Baymbajav Medicine.2018; 97(7): e9756. CrossRef
Using the chronic kidney disease guidelines to evaluate the renal safety of tenofovir disoproxil fumarate in hepatitis B patients H. J. Tsai, Y. W. Chuang, S. W. Lee, C. Y. Wu, H. Z. Yeh, T. Y. Lee Alimentary Pharmacology & Therapeutics.2018; 47(12): 1673. CrossRef
First
Prev
